Recordati

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Pro Farma is a distributor of pharmaceutical products, focusing on the sourcing and distribution of both prescription and over-the-counter medications in Switzerland. The company specializes in selected therapeutic areas and also offers a variety of services tailored for pharmaceutical companies, extending its reach beyond Swiss borders.

Italchimici Spa, along with its subsidiaries, produces and supplies raw materials.

Casen Fleet is a pharmaceutical manufacturer based in Madrid, Spain, focusing on the development, clinical research, production, and marketing of products primarily in gastroenterology and women's health. The company's facility in Zaragoza spans 23,000 square meters and has undergone significant expansions and renovations since its establishment in 1985, with substantial upgrades completed in 2002 and the addition of a new laboratory for product development finalized in 2007. Casen Fleet is dedicated to creating specialist endorsed products that cater to the specific needs of its target markets.

Opalia Pharma S.A., established in 1988 and based in Ariana, Tunisia, specializes in the manufacture and marketing of generic pharmaceutical products. The company focuses on therapeutic areas such as dermatology, gastrointestinal, and respiratory diseases, offering a range of medicinal forms including liquids, creams, ointments, gels, suppositories, and pessaries. In addition to its manufacturing capabilities, Opalia Pharma provides various services, including the development and procurement of components, regulatory compliance, and pharmaceutical release. The company also engages in galenical and analytical development, offering services such as formulation, primary packaging, and the production of experimental batches. As of 2014, Opalia Pharma operates as a subsidiary of Recordati Industria Chimica e Farmaceutica S.p.A.

Farma-Projekt Sp. z o.o. produces various dietary supplements. Its products include Gastro Up, a dietary supplement for the functioning of digestive tract; Inhepax.

Orphan Europe SARL is a pharmaceutical company that specializes in the development of orphan medicinal products aimed at treating rare metabolic disorders. The company's portfolio includes several key products, such as Cystadane, Cystagon, Normosang, and Wilzin, which provide patients with essential treatment options for their specific health needs. By focusing on orphan drugs, Orphan Europe addresses the challenges faced by individuals with rare diseases, ensuring they have access to vital therapies under one umbrella.